发布求助
文献互助 智能选刊 最新文献

Critical Reviews in Oncogenesis最新文献

筛选
英文 中文
Fifty Years of Diazeniumdiolate Research: A Tribute to Dr. Larry K. Keefer. 二酸二氮鎓研究五十年：向拉里·K·基弗博士致敬。
Critical Reviews in Oncogenesis Pub Date : 2023-01-01 DOI: 10.1615/CritRevOncog.2023048491
Khosrow Kashfi
{"title":"Fifty Years of Diazeniumdiolate Research: A Tribute to Dr. Larry K. Keefer.","authors":"Khosrow Kashfi","doi":"10.1615/CritRevOncog.2023048491","DOIUrl":"10.1615/CritRevOncog.2023048491","url":null,"abstract":"<p><p>The pioneering studies of Dr. Larry Keefer and colleagues with diazeniumdiolates or NONOates as a platform have unraveled the chemical biology of many nitric oxides and have led to the design of a variety of promising therapeutic agents in oncology, gastroenterology, antimicrobials, wound healing, and the like. This dedication to Dr. Larry Keefer briefly highlights some of his studies using the diazeniumdiolate platform in the cancer arena.</p>","PeriodicalId":35617,"journal":{"name":"Critical Reviews in Oncogenesis","volume":"28 1","pages":"47-55"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11076142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41214820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Chemical Biology of NO that Regulates Oncogenic Signaling and Metabolism: NOS2 and Its Role in Inflammatory Disease. 调节致癌信号和代谢的NO的化学生物学：NOS2及其在炎症性疾病中的作用。
Critical Reviews in Oncogenesis Pub Date : 2023-01-01 DOI: 10.1615/CritRevOncog.2023047302
Katrina M Miranda, Lisa A Ridnour, Robert Y S Cheng, David A Wink, Douglas D Thomas
{"title":"The Chemical Biology of NO that Regulates Oncogenic Signaling and Metabolism: NOS2 and Its Role in Inflammatory Disease.","authors":"Katrina M Miranda, Lisa A Ridnour, Robert Y S Cheng, David A Wink, Douglas D Thomas","doi":"10.1615/CritRevOncog.2023047302","DOIUrl":"10.1615/CritRevOncog.2023047302","url":null,"abstract":"<p><p>Nitric oxide (NO) and the enzyme that synthesizes it, nitric oxide synthase 2 (NOS2), have emerged as key players in inflammation and cancer. Expression of NOS2 in tumors has been correlated both with positive outcomes and with poor prognoses. The chemistry of NO is the major determinate to the biological outcome and the concentration of NO, which can range over five orders of magnitude, is critical in determining which pathways are activated. It is the activation of specific oncogenic and immunological mechanisms that shape the outcome. The kinetics of specific reactions determine the mechanisms of action. In this review, the relevant reactions of NO and related species are discussed with respect to these oncogenic and immunological signals.</p>","PeriodicalId":35617,"journal":{"name":"Critical Reviews in Oncogenesis","volume":"28 1","pages":"27-45"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11318306/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41214825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preface 前言
Critical Reviews in Oncogenesis Pub Date : 2022-12-16 DOI: 10.1109/ASE.2006.54
Benjamin Bonavida
{"title":"Preface","authors":"Benjamin Bonavida","doi":"10.1109/ASE.2006.54","DOIUrl":"https://doi.org/10.1109/ASE.2006.54","url":null,"abstract":"","PeriodicalId":35617,"journal":{"name":"Critical Reviews in Oncogenesis","volume":"27 2 1","pages":"xiii-xiv"},"PeriodicalIF":0.0,"publicationDate":"2022-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1109/ASE.2006.54","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43515587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improving Radiotherapy Response in the Treatment of Head and Neck Cancer. 改善头颈癌治疗中的放疗反应。
Critical Reviews in Oncogenesis Pub Date : 2022-01-01 DOI: 10.1615/CritRevOncog.2022044635
Christina A Wicker, Taylor Petery, Poornima Dubey, Trisha M Wise-Draper, Vinita Takiar
{"title":"Improving Radiotherapy Response in the Treatment of Head and Neck Cancer.","authors":"Christina A Wicker, Taylor Petery, Poornima Dubey, Trisha M Wise-Draper, Vinita Takiar","doi":"10.1615/CritRevOncog.2022044635","DOIUrl":"10.1615/CritRevOncog.2022044635","url":null,"abstract":"<p><p>The application of radiotherapy to the treatment of cancer has existed for over 100 years. Although its use has cured many, much work remains to be done to minimize side effects, and in-field tumor recurrences. Resistance of the tumor to a radiation-mediated death remains a complex issue that results in local recurrence and significantly decreases patient survival. Here, we review mechanisms of radioresistance and selective treatment combinations that improve the efficacy of the radiation that is delivered. Further investigation into the underlying mechanisms of radiation resistance is warranted to develop not just novel treatments, but treatments with improved safety profiles relative to current radiosensitizers. This review is written in memory and honor of Dr. Peter Stambrook, an avid scientist and thought leader in the field of DNA damage and carcinogenesis, and a mentor and advocate for countless students and faculty.</p>","PeriodicalId":35617,"journal":{"name":"Critical Reviews in Oncogenesis","volume":"27 2","pages":"73-84"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228519/pdf/nihms-1897750.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9595415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Alterations in BRCA2 as Determinants of Therapy Response in Prostate Cancer. BRCA2 的改变是前列腺癌治疗反应的决定因素。
Critical Reviews in Oncogenesis Pub Date : 2022-01-01 DOI: 10.1615/CritRevOncog.2022043233
Mia Hofstad, Emily Y Huang, Andrea Woods, Yi Yin, Neil B Desai, Ganesh V Raj
{"title":"Alterations in BRCA2 as Determinants of Therapy Response in Prostate Cancer.","authors":"Mia Hofstad, Emily Y Huang, Andrea Woods, Yi Yin, Neil B Desai, Ganesh V Raj","doi":"10.1615/CritRevOncog.2022043233","DOIUrl":"10.1615/CritRevOncog.2022043233","url":null,"abstract":"<p><p>Prostate cancer (PCa) is one of the leading causes of cancer diagnoses and cancer-related deaths in the United States. Mutations or deletions in the genes involved in the DNA damage response (DDR) are common in aggressive primary PCa (germline alterations) and further enriched in advanced therapy-resistant PCa (somatic alterations). Among the DDR genes, BRCA2 is the most commonly altered (~ 13%) in advanced therapy-resistant PCa. Patients with BRCA2-altered PCas are exquisitely sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis). Indeed, two PARPis-olaparib and rucaparib have recently gained U.S. Food & Drug Administration approval for the treatment of advanced PCas harboring a BRCA2 mutation. This review seeks to explore the role of BRCA2 in DNA damage repair, the pathogenesis and progression of BRCA2 mutant PCa, and the utility of radiation therapy, targeted therapies, and platinum-based chemotherapies for patients with BRCA2 alterations.</p>","PeriodicalId":35617,"journal":{"name":"Critical Reviews in Oncogenesis","volume":" ","pages":"81-96"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40417037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genomic Alterations to Guide Treatment Selection in Metastatic Prostate Cancer. 基因组改变指导转移性前列腺癌的治疗选择。
Critical Reviews in Oncogenesis Pub Date : 2022-01-01 DOI: 10.1615/CritRevOncog.2022043298
Amy Davies, Arun A Azad, Edmond M Kwan
{"title":"Genomic Alterations to Guide Treatment Selection in Metastatic Prostate Cancer.","authors":"Amy Davies,&nbsp;Arun A Azad,&nbsp;Edmond M Kwan","doi":"10.1615/CritRevOncog.2022043298","DOIUrl":"https://doi.org/10.1615/CritRevOncog.2022043298","url":null,"abstract":"<p><p>Treatment options for men with metastatic prostate cancer have greatly expanded in the last decade. Androgen receptor pathway inhibitors, taxane cytotoxic therapy, poly(ADP-ribose) polymerase inhibitors, and radionuclide theranostics against prostate-specific membrane antigen have collectively contributed to incremental improvements in both quality and longevity of life for patients with metastatic castration-resistant prostate cancer (mCRPC). Despite these successes, few studies inform on optimal therapy selection and sequencing across this crowded treatment landscape. Genomic analysis of both tissue and liquid biopsy specimens shows promise in bridging this practice gap, with alterations in several key prostate cancer driver genes demonstrating clear associations with clinical outcomes, as well as informing use of novel precision medicine targeted therapies. In this review, we evaluate the current evidence of genomic alterations in various oncogenic signaling pathways as clinical biomarkers in mCRPC, focusing on correlative studies that analyzed outcomes based on findings in plasma cell-free DNA. We highlight the pitfalls of interpreting genomic findings in samples with substandard tumor content, and suggest pathologic and disease factors to consider when embarking upon tumor genotyping to guide treatment decisions in metastatic prostate cancer. As access to life-prolonging therapies improves, and barriers to cost-effective genotyping and reliable data interpretation are overcome, we anticipate that predictive and prognostic biomarkers that inform on disease biology, drug sensitivity, and therapy resistance will inevitably be integrated into the routine care of patients with metastatic prostate cancer.</p>","PeriodicalId":35617,"journal":{"name":"Critical Reviews in Oncogenesis","volume":" ","pages":"61-80"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40417036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Technologies for Size-Based Analysis of Circulating Cell-Free DNA: Limitations and Clinical Implementation. 基于尺寸的循环无细胞DNA分析技术:局限性和临床应用。
Critical Reviews in Oncogenesis Pub Date : 2022-01-01 DOI: 10.1615/CritRevOncog.2022043215
Thomas Pataillot-Meakin, Sylvain Ladame, Charlotte Bevan
{"title":"Technologies for Size-Based Analysis of Circulating Cell-Free DNA: Limitations and Clinical Implementation.","authors":"Thomas Pataillot-Meakin,&nbsp;Sylvain Ladame,&nbsp;Charlotte Bevan","doi":"10.1615/CritRevOncog.2022043215","DOIUrl":"https://doi.org/10.1615/CritRevOncog.2022043215","url":null,"abstract":"<p><p>Prostate cancer is the second most common malignancy in men worldwide, and incidence is likely to rise in the next decade. The current screening options have limitations and have been shown to result in over-treatment of clinically insignificant disease. New biomarkers and technologies to detect them are therefore needed to better diagnose and stratify patients in primary care. Circulating cell-free DNA (ccfDNA) has gained interest as a potential minimally invasive biomarker, detectable in many bodily fluids (such as blood, urine, and cerebral spinal fluid) and reflecting the mutational landscape in tumors. More recently, the size distribution of ccfDNA fragments has also gained interest as a specific biomarker, where differences in size distribution have been observed between healthy volunteers and cancer patients, resulting in the new field of fragmentomics. Analysis of ccfDNA sizes provides avenues for alternative analytical technologies but commercial options are currently limited. Most focus on mutation detection and are subject to several biases that may affect size distribution. Here, we discuss the available technologies and identify major issues and considerations that may affect their implementation as a clinically useful test based on ccfDNA size profiling.</p>","PeriodicalId":35617,"journal":{"name":"Critical Reviews in Oncogenesis","volume":" ","pages":"97-108"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40417038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of the Tumor Microenvironment and the Influence of Epigenetics on the Tumor Microenvironment in Oral Carcinogenesis: Potential Implications. 肿瘤微环境在口腔癌变中的作用及表观遗传学对肿瘤微环境的影响:潜在意义。
Critical Reviews in Oncogenesis Pub Date : 2022-01-01 DOI: 10.1615/CritRevOncog.2022047088
Sagar Dholariya, Ragini D Singh, Madhuri Radadiya, Deepak Parchwani, Gaurav Sharma, Rashid Mir
{"title":"Role of the Tumor Microenvironment and the Influence of Epigenetics on the Tumor Microenvironment in Oral Carcinogenesis: Potential Implications.","authors":"Sagar Dholariya, Ragini D Singh, Madhuri Radadiya, Deepak Parchwani, Gaurav Sharma, Rashid Mir","doi":"10.1615/CritRevOncog.2022047088","DOIUrl":"10.1615/CritRevOncog.2022047088","url":null,"abstract":"<p><p>Oral cancer has become a significant problem throughout the world, particularly in countries that are still developing. Recent literature supports the contribution of components of the tumor microenvironment (TME) and the effect of epigenetic changes happening in the cells of the TME on oral cancer development and progression. In this review, we comprehensively examine the significance of TME in the development of OC along with the current understanding of the epigenetic modifications that regulate the TME and their cohesive impact on tumor traits and their potential as therapeutic targets.</p>","PeriodicalId":35617,"journal":{"name":"Critical Reviews in Oncogenesis","volume":"27 4","pages":"47-64"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9678859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic Adjuncts in Oral Cancer Evaluation. 口腔癌评估中的诊断辅助工具。
Critical Reviews in Oncogenesis Pub Date : 2022-01-01 DOI: 10.1615/CritRevOncog.2022047079
Daksh Goel, Siddharth Shah, Manish Mair
{"title":"Diagnostic Adjuncts in Oral Cancer Evaluation.","authors":"Daksh Goel,&nbsp;Siddharth Shah,&nbsp;Manish Mair","doi":"10.1615/CritRevOncog.2022047079","DOIUrl":"https://doi.org/10.1615/CritRevOncog.2022047079","url":null,"abstract":"<p><p>Oral cancer is a major health concern in developing countries like India which contributes one-third of the global oral cancer burden. Unlike other non-head and neck malignancies, oral cancer has a more curative treatment course. If detected early, oral cancer has the best treatment outcomes. However, most oral cancer has a dismal five-year survival rate as the majority are diagnosed in late/advanced loco-regional stages. Current methods of assessment for oral cancer include, thorough clinical examination under white light and biopsy. Over the years, a number of diagnostic tools have been created as adjuncts to white light evaluation to help with the early diagnosis of oral cancer. This article's goal is to discuss the present diagnostic techniques for oral cancer as well as potential future uses of cutting-edge, innovative technology for the detection of the disease. This may expand our diagnostic choices and enhance our capacity to accurately identify and manage lesions associated with oral cancer.</p>","PeriodicalId":35617,"journal":{"name":"Critical Reviews in Oncogenesis","volume":"27 4","pages":"39-45"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9681963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From Research to the Real World: Moving Prostate Cancer Biomarkers into the Clinic. 从研究到现实世界:将前列腺癌生物标志物转移到临床。
Critical Reviews in Oncogenesis Pub Date : 2022-01-01 DOI: 10.1615/CritRevOncog.2022043394
Kate Mahon
{"title":"From Research to the Real World: Moving Prostate Cancer Biomarkers into the Clinic.","authors":"Kate Mahon","doi":"10.1615/CritRevOncog.2022043394","DOIUrl":"https://doi.org/10.1615/CritRevOncog.2022043394","url":null,"abstract":"<p><p>Effective biomarkers provide the potential to significantly improve treatment decisions and outcomes in prostate cancer patients. While the literature is inundated with prostate cancer biomarkers in the early phases of testing, very few reach the clinic. Research should be focused on progressing effective biomarkers from discovery to clinical utility and implementation. Presented here is an overview of the biomarker development pathway and a discussion of the current issues impeding our efforts to deliver biomarkers that improve clinical outcomes in men with prostate cancer.</p>","PeriodicalId":35617,"journal":{"name":"Critical Reviews in Oncogenesis","volume":" ","pages":"109-119"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40417039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信